While preclinical data are intriguing, these diets are difficult for patients to maintain and have yet to show clear clinical benefit, remaining a niche but noteworthy approach within the broader landscape of AMPK-focused cancer therapy. This evidence concerns the gene PRKAA2 and cancer.